Get started
Author

Caner Acar

Observed names: ACAR, Caner, Acar, Caner, Caner ACAR
ORCID: 0000-0002-9782-6807
Observed ORCID: 0000-0002-9782-6807
OpenAlex ID: A5074119627
Toxicity of the Lessepsian pufferfish Lagocephalus sceleratus from eastern Mediterranean coasts of Turkey and species identification by rapid PCR amplification
2016 · Caner Acar, Shoichiro Ishizaki, et al. · European Food Research and Technology · 26
Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapy
2025 · Caner Acar, Haydar Çağatay Yüksel, et al. · Clinical & Translational Oncology · 22
Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study
2024 · Salih Tünbekici, Haydar cagatay Yuksel, et al. · Cancers · 11
PDF
Predicting immune-related adverse events in patients with melanoma: the role of interleukin-7 rs16906115 polymorphism and lymphocyte dynamics
2025 · Fatma Pınar Açar, Caner Acar, et al. · Frontiers in Immunology · 9
PDF
Rare immune-related adverse effect of pembrolizumab: pulmonary hypertension
2024 · Caner Acar, Gökhan Sahin, et al. · Journal of Chemotherapy · 8
Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma
2025 · Gökhan Şahin, Caner Acar, et al. · Clinical & Translational Oncology · 7
Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes
2025 · Caner Acar, Haydar Çağatay Yüksel, et al. · Expert Review of Anticancer Therapy · 7
Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
2024 · Caner Acar, Haydar Çağatay Yüksel, et al. · Discover Oncology · 7
PDF
Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment
2025 · Caner Acar, Fatma Pinar Açar, et al. · BMC Cancer · 6
Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab
2025 · Gökhan Şahin, Caner Acar, et al. · Journal of Clinical Medicine · 6
C-reactive protein kinetics as prognostic biomarkers in advanced melanoma treated with immune checkpoint inhibitors
2025 · Caner Acar, Haydar Çağatay Yüksel, et al. · Melanoma Research · 5
Biomarker diversity in increased inflammation: Secondary hemophagocytic syndrome vs. systemic inflammatory response syndrome
2022 · Sukriye Miray Kilincer Bozgul, Gunes Ak, et al. · International Journal of Laboratory Hematology · 5
Assessment of the fear of progression in Turkish cancer patients: a validation and reliability study fear of progression questionnaire short form
2025 · Gökhan Şahin, Haydar C. Yuksel, et al. · BMC Psychology · 4
PDF
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
2024 · İsmail Beypınar, Hacer Demir, et al. · Breast Cancer Research and Treatment · 4
Integrating neutrophils, lymphocytes and eosinophils: development and validation of the NLE Index in ICI-treated metastatic melanoma
2025 · Fatma Pinar Açar, Caner Acar, et al. · Melanoma Research · 3
Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
2024 · Caner Acar, Haydar Çağatay Yüksel, et al. · Current Oncology · 3
PDF
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events
2026 · Caner Acar, Gökhan Şahin, et al. · Expert Review of Anticancer Therapy · 2
LASSO-Driven Selection of Biochemical and Clinical Markers for Primary Resistance to PD-1 Inhibitors in Metastatic Melanoma
2025 · Haydar C. Yuksel, Caner Acar, et al. · Medicina · 2
PDF
Outcomes of patients with sepsis due extensively drug-resistant bacterial infections with and without polyspecific intravenous immunoglobulin therapy: A retrospective study
2025 · Caner Acar, Sukriye Miray Kilincer Bozgul, et al. · Medicine · 2
XGBoost outperforms other machine learning models in diagnosing Sepsis-Associated Thrombocytopenia: a multicenter retrospective study
2026 · Busra Emir, Evrim Ozmen, et al. · Frontiers in Medicine · 1
PDF
Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors
2025 · Fatma Pinar Açar, Caner Acar, et al. · Expert Review of Anticancer Therapy · 1
Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study
2025 · Salih Tunbekici, Gokhan Sahin, et al. · Discover Oncology · 1
PDF
Association between immune-related adverse events and recurrence dynamics under adjuvant anti–PD-1 therapy in resected melanoma
2025 · Gökhan Şahin, Caner Acar, et al. · Frontiers in Oncology · 1
PDF
Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group
2025 · Gökhan Şahin, Esmanur Kaplan Tüzün, et al. · International Journal of Cancer · 1
Efficacy and Safety of the Topotecan–Cyclophosphamide Regimen in Adult Metastatic Ewing Sarcoma: A Large, Multicenter, Real-World Study
2025 · Salih Tunbekici, Haydar Cagatay Yuksel, et al. · Cancers · 1
PDF
Works count: 51
Citation count: 146
H-index: 7
I10-index: 3
Year
Topic
Type